No more than 15 authors can be listed.Please ensure the authors are listed in the right order.If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.
Medications for chronic obstructive pulmonary disease (COPD) may be less efficacious in active smokers. In BOREAS and NOTUS, dupilumab reduced exacerbations and improved lung function in patients with COPD and type 2 inflammation. This post hoc analysis evaluates dupilumab efficacy in current and former smokers with COPD.
In phase 3 BOREAS (NCT03930732) and NOTUS (NCT04456673), patients with COPD on triple therapy, with moderate-to-severe airflow limitation and type 2 inflammation (screening eosinophils ≥300 cells/µL) received add-on dupilumab 300 mg every 2 weeks or placebo for 52 weeks. Endpoints were: adjusted annualized moderate or severe exacerbation rate, as well as change from baseline in pre-bronchodilator forced expiratory volume in 1 second (pre-bronchodilator FEV1) and Evaluating Respiratory Symptoms in COPD (E-RS:COPD) score by smoking status. Lower E-RS:COPD scores indicate improved symptom control.
Dupilumab reduced exacerbation relative risk vs placebo by 32% (dupilumab: n=662; placebo: n=654) (relative risk vs placebo: 0.68; 95% CI: 0.57, 0.81; P<0.001) and 31% (dupilumab: n=276; placebo: n=282) (relative risk: 0.69; 95% CI: 0.53, 0.89; P=0.005) in former and current smokers, respectively. At Week 12, dupilumab improved pre-bronchodilator FEV1 in former (LS mean difference vs placebo: 88 mL; 95% CI: 50, 126; P<0.001) and current smokers (64 mL; 95% CI: 19, 109; P=0.005) (interaction P value: 0.36). At Week 52, dupilumab also improved E-RS:COPD scores in former (LS mean difference vs placebo: –0.9 points; 95% CI: –1.5, –0.3; P=0.004) and current smokers (LS mean difference vs placebo: –1.0 points; 95% CI: –2.0, –0.1; P=0.024) (interaction P value: 0.33).
Dupilumab reduced exacerbations and symptom severity while improving lung function in patients with COPD and type 2 inflammation, regardless of smoking status. These findings underscore the potential of dupilumab as an effective treatment, particularly for active smokers with COPD, who depending on geographical area may have limited therapeutic options.